GamaMabs to use AstraZeneca's technology in hunt for new ADC therapy

France’s GamaMabs Pharma and MedImmune, AstraZeneca’s biologics arm, have entered into a licensing agreement to try to produce an antibody-drug conjugate (ADC) as a potential cancer therapy.

GamaMabs will have the exclusive right to use Astra’s ‘PBD toxin’ and linker technology to develop an ADC against a single target, suitable as a therapeutic for a broad variety of solid tumors.

AstraZeneca will receive an upfront payment, development and commercial milestone payments, as well as royalties on net sales.

GamaMabs is focused on developing optimized therapeutic antibodies targeting proteins encoded by the AMHR2 gene.